📣 VC round data is live. Check it out!

Myriad Genetics Valuation Multiples

Discover Myriad Genetics' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Medios, Perspective Therapeutics, Vicenne, Orthofix Medical and more.

Myriad Genetics Overview

About Myriad Genetics

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.


Founded

1992

HQ

United States

Employees

2.7K

Website

myriad.com

Financials (LTM)

Revenue: $841M
EBITDA: $38M

EV

$493M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Myriad Genetics Financials

Myriad Genetics reported last 12-month revenue of $841M and EBITDA of $38M.

In the same LTM period, Myriad Genetics generated $584M in gross profit, $38M in EBITDA, and $5M in net income.

Revenue (LTM)


Myriad Genetics P&L

In the most recent fiscal year, Myriad Genetics reported revenue of $825M and EBITDA of $39M.

Myriad Genetics is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 5%, and net margin of 1%.

See analyst estimates for Myriad Genetics
LTMLast FY202320242025202620272028
Revenue$841M$825M$753M$838M$825M
Gross Profit$584M$577M$517M$585M$577M
Gross Margin69%70%69%70%70%
EBITDA$38M$39M($197M)($60M)($331M)
EBITDA Margin5%5%(26%)(7%)(40%)
EBIT Margin2%2%(19%)(11%)(8%)
Net Profit$5M$6M($263M)($127M)($366M)
Net Margin1%1%(35%)(15%)(44%)

Financial data powered by Morningstar, Inc.

Myriad Genetics Stock Performance

Myriad Genetics has current market cap of $406M, and enterprise value of $493M.

Market Cap Evolution


Myriad Genetics' stock price is $4.30.

Myriad Genetics share price increased by 7.5% in the last 30 days, and decreased by 19.0% in the last year.

Myriad Genetics has an EPS (earnings per share) of $0.06.

See more trading valuation data for Myriad Genetics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$493M$406M0.6%7.5%-4.4%-19.0%$0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Myriad Genetics Valuation Multiples

Myriad Genetics trades at 0.6x EV/Revenue multiple, and 12.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Myriad Genetics

EV / Revenue (LTM)


Myriad Genetics Financial Valuation Multiples

As of June 3, 2026, Myriad Genetics has market cap of $406M and EV of $493M.

Myriad Genetics has a P/E ratio of 77.7x.

LTMLast FY202320242025202620272028
EV/Revenue0.6x0.6x0.7x0.6x0.6x
EV/EBITDA12.8x12.7x(2.5x)(8.3x)(1.5x)
EV/EBIT37.5x32.4x(3.4x)(5.6x)(7.3x)
EV/Gross Profit0.8x0.9x1.0x0.8x0.9x
P/E77.7x70.0x(1.5x)(3.2x)(1.1x)
EV/FCF-(19.3x)(2.7x)(12.8x)(19.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Myriad Genetics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Myriad Genetics Margins & Growth Rates

Myriad Genetics grew revenue by 5% but EBITDA decreased by 3% in the last fiscal year.

In the most recent fiscal year, Myriad Genetics reported gross margin of 70%, EBITDA margin of 5%, and net margin of 1%.

See estimated margins and future growth rates for Myriad Genetics

Myriad Genetics Margins

Last FY202420252026202720282029
Gross Margin70%70%70%69%
EBITDA Margin5%(7%)(40%)4%
EBIT Margin2%(11%)(8%)1%
Net Margin1%(15%)(44%)1%
FCF Margin(3%)(5%)(3%)-

Myriad Genetics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%11%(2%)5%
Gross Profit Growth3%13%(2%)3%
EBITDA Growth(3%)(70%)456%(111%)
EBIT Growth(32%)(39%)(23%)(115%)
Net Profit Growth(23%)(52%)187%(101%)
FCF Growth-(79%)(33%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Myriad Genetics Operational KPIs

Myriad Genetics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Myriad Genetics' Rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Myriad Genetics' Rule of X is 16% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Myriad Genetics
LTMLast FY202320242025202620272028
Rule of 4010%9%---
Bessemer Rule of X18%16%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue-34%-34%34%
G&A Expenses to Revenue-31%76%33%31%
R&D Expenses to Revenue12%13%12%14%13%
Opex to Revenue-78%88%80%78%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Myriad Genetics Competitors

Myriad Genetics competitors include Medios, Perspective Therapeutics, Vicenne, Orthofix Medical, Abclon, OrthoPediatrics, Coltene, TaiDoc Technology, Universal Vision and IVF hartmann.

Most Myriad Genetics public comparables operate across Diagnostics & Genomics, Laboratory Services, Medical Devices, BioTech, DeepTech and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medios0.3x0.2x7.5x5.4x
Perspective Therapeutics162.7x213.0x(1.4x)(1.2x)
Vicenne2.9x-12.6x-
Orthofix Medical0.7x0.6x6.4x6.2x
Abclon130.0x-(37.5x)-
OrthoPediatrics2.0x1.9x32.8x25.2x
Coltene1.3x1.4x11.4x11.1x
TaiDoc Technology1.8x-4.1x-

This data is available for Pro users. Sign up to see all Myriad Genetics competitors and their valuation data.

Start Free Trial

Acquisitions by Myriad Genetics

Myriad Genetics has acquired 6 companies to date.

Last acquisition by Myriad Genetics was on November 1st 2022. Myriad Genetics acquired Gateway Genomics for $110M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Myriad Genetics

Gateway Genomics
Counsyl
Assurerx Health
Sividon Diagnostics
Description
Gateway Genomics is a biotechnology company developing non-invasive prenatal tests using cell-free fetal DNA. Based in San Diego, California, it commercializes SneakPeek Early Gender DNA Test, available from 6 weeks gestation with 99.9% accuracy validated in clinical studies. The company processes over 1 million tests annually through its CLIA-certified lab, shipping kits directly to consumers and clinics across the US. Founded in 2013, Gateway Genomics partners with major retailers like Walmart for at-home testing kits.
Counsyl is a health technology company providing DNA screening services. Based in South San Francisco, it operates a CLIA-certified laboratory for reproductive, pregnancy, and cancer tests. The platform serves patients and healthcare providers nationwide with real-time result reporting.
AssureRx Health is a personalized medicine provider offering genetic testing through the GeneSight assay to guide medication selection for behavioral health and chronic pain treatments. Clinicians use its pharmacogenomic reports to match patients with antidepressants, antipsychotics, and analgesics based on DNA analysis. The Mason, Ohio-based company partners with healthcare providers to improve outcomes in psychiatry and neurology.
Sividon Diagnostics is a Cologne-based developer of companion diagnostics for oncology. Spun out from Siemens Healthcare Diagnostics, the company enhances molecular tests for breast cancer and other malignancies to support individualized treatment decisions. Sividon leverages an international network of experts and holds intellectual property rights dating back to 2004 in molecular diagnostics. Its scientists and managers focus on evidence-based assays integrated into clinical workflows across Europe.
HQ CountryFranceUnited StatesUnited StatesGermany
HQ City
Montpellier
San Francisco, CA
Cincinnati, OH
Hamburg
Deal Date1 Nov 202228 May 20183 Aug 201631 May 2016
Valuation$110M$375M$225M$39M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Myriad Genetics acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Myriad Genetics

Myriad Genetics has invested in 1 company to date.

Latest investment by Myriad Genetics was on April 29th 2013. Myriad Genetics invested in RainDance Technologies in their $20M Series E round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Myriad Genetics

RainDance Technologies
Description
RainDance Technologies is a medical technology firm specializing in droplet digital PCR platforms for life sciences research. Solutions support non-invasive liquid biopsies, single-cell analysis, molecule detection, and mutation identification in cancer studies. Services extend to diagnostics and reaction methodologies. Acquired by Bio-Rad Laboratories in 2016 and headquartered in Lexington, Massachusetts, the technology advances precision medicine applications in oncology and genomics.
HQ CountryUnited States
HQ City
Lowell, MA
Deal Date29 Apr 2013
RoundSeries E
Raised$20M
InvestorsAcadia Woods Partners; Alloy Ventures; Mohr Davidow Ventures; Myriad Genetics; Quaker BioVentures; Sectoral Asset Management
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Myriad Genetics investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Myriad Genetics

When was Myriad Genetics founded?Myriad Genetics was founded in 1992.
Where is Myriad Genetics headquartered?Myriad Genetics is headquartered in United States.
How many employees does Myriad Genetics have?As of today, Myriad Genetics has over 2K employees.
Who is the CEO of Myriad Genetics?Myriad Genetics' CEO is Samraat S. Raha.
Is Myriad Genetics publicly listed?Yes, Myriad Genetics is a public company listed on Nasdaq.
What is the stock symbol of Myriad Genetics?Myriad Genetics trades under MYGN ticker.
When did Myriad Genetics go public?Myriad Genetics went public in 1995.
Who are competitors of Myriad Genetics?Myriad Genetics main competitors include Medios, Perspective Therapeutics, Vicenne, Orthofix Medical, Abclon, OrthoPediatrics, Coltene, TaiDoc Technology, Universal Vision, IVF hartmann.
What is the current market cap of Myriad Genetics?Myriad Genetics' current market cap is $406M.
What is the current revenue of Myriad Genetics?Myriad Genetics' last 12 months revenue is $841M.
What is the current revenue growth of Myriad Genetics?Myriad Genetics revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Myriad Genetics?Current revenue multiple of Myriad Genetics is 0.6x.
What is the current EBITDA of Myriad Genetics?Myriad Genetics' last 12 months EBITDA is $38M.
What is Myriad Genetics' EBITDA margin?Myriad Genetics' last 12 months EBITDA margin is 5%.
What is the current EV/EBITDA multiple of Myriad Genetics?Current EBITDA multiple of Myriad Genetics is 12.8x.
How many companies Myriad Genetics has acquired to date?As of June 2026, Myriad Genetics has acquired 6 companies.
What was the largest acquisition by Myriad Genetics?$375M acquisition of Counsyl on 28th May 2018 was the largest M&A Myriad Genetics has done to date.
What companies Myriad Genetics acquired?Myriad Genetics acquired Counsyl, Crescendo Bioscience, Assurerx Health, Gateway Genomics, Sividon Diagnostics, and Privatklinik Dr. Robert Schindlbeck.
In how many companies Myriad Genetics has invested to date?As of June 2026, Myriad Genetics has invested in 1 company.
What was the last Myriad Genetics investment?On 29th April 2013 Myriad Genetics invested in RainDance Technologies, participating in a $20M Series E round, alongside Acadia Woods Partners, Alloy Ventures, Mohr Davidow Ventures, Quaker BioVentures, and Sectoral Asset Management.
In what companies Myriad Genetics invested in?Myriad Genetics invested in RainDance Technologies.

See public comps similar to Myriad Genetics

Lists including Myriad Genetics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial